Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01176461 · ClinicalTrials.gov registry record · Phase 1
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
A Phase 1 study of Melanoma (Skin), sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT01176461 is a Phase 1 study of Melanoma (Skin) that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 127 participants, roughly in line with the 133-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01176461, a Phase 1 study of Melanoma (Skin), has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine. The purpose of this study is to test the side effects of an investigational vaccine with an immune booster. Investigators also wish to find out its effects on the patient's immune system and whether it will shrink their melanoma.
Conditions Studied
Interventions
- DRUG Montanide ISA 51 VG
- BIOLOGICAL gp100:209-217(210M)
- BIOLOGICAL MART-1
- BIOLOGICAL NY-ESO-1
- BIOLOGICAL gp100:280-288(288V)
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2010-08-04 |
| Est. Completion | 2016-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01176461
The ClinicalTrials.gov registry entry for NCT01176461 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 133-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 5 interventions - of which Montanide ISA 51 VG is the first listed.
NCT01176461 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01176461 about?
NCT01176461 is a clinical study titled "Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558". This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine. The purpose of this study is to test the side effects of an investigational vaccine with an immune booster. Investigators also wish to find out its e...
What is the current status of trial NCT01176461?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2010-08-04. Estimated completion is 2016-12-12.
What conditions does trial NCT01176461 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT01176461?
The interventions under investigation include: Montanide ISA 51 VG (DRUG), gp100:209-217(210M) (BIOLOGICAL), MART-1 (BIOLOGICAL), NY-ESO-1 (BIOLOGICAL), gp100:280-288(288V) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01176461?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01176461 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.